Video Player
Better
00:00
00:00
Better
Treatments,
More Tomorrows
Video PlayerBetter
00:00
00:00
Better
Treatments,
More Tomorrows
We are
Advancing
A late-stage pipeline of product candidates for the treatment of hard-to-treat tumors and viruses.
Innovative
Therapies
Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).
Innovative
Therapies
Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).
AML Clinical Day Featuring Clinicians Martin S. Tallman, MD and Michael Andreeff, MD, PhD
May 7, 2024
Priority Development Pipeline
AML Patient Journey and the Annamycin Opportunity
Latest Releases
24 Mar 2025Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
- Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first ...
19 Mar 2025Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" o...
11 Mar 2025Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
On-demand video webcast now available here HOUSTON, March 11, 2025 /PRNewswire/ -- Moleculin Biotech...
Stock Information
NASDAQ: MBRX
NASDAQ: MBRX
$1.04 ▼ $-0.01 (-0.95%)
3/28/2025 4:03 PM
Corporate
Presentation
$1.04 ▼ $-0.01 (-0.95%)
3/28/2025 4:03 PM
Corporate
Presentation
